Agilent Technologies (A) Fundamentals 2026 — P/E 27.1x, Revenue Analysis | SniperIQ
Agilent Technologies (A) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Agilent Technologies (A) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
Agilent Technologies (A) has a market capitalization of approximately
Agilent Technologies's trailing twelve-month P/E ratio is 27.1x, with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Agilent Technologies runs a net profit margin of 19.6%, a gross margin of 53.0%, and an operating margin of 21.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Agilent Technologies reported revenue of $6.9B for fiscal year 2025, with net income of
Agilent Technologies offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Agilent Technologies carries a debt-to-equity ratio of 0.47x and a current ratio of 2.10x, with a market beta of 1.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Agilent Technologies (A) the key facts are: market cap
Get Agilent Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.